Get the Stockscreener App
41.40
0.36%
-0.14
Merus N V stock is traded at $41.40, with a volume of 286.83K.
It is down -0.36% in the last 24 hours and down -4.39% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$41.54
Open:
$42.61
24h Volume:
286.83K
Relative Volume:
0.51
Market Cap:
$2.84B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-10.48
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+1.10%
1M Performance:
-4.39%
6M Performance:
-15.53%
1Y Performance:
+8.75%
1-Day Range:
$41.00
$42.61
1-Week Range:
$39.49
$43.35
52-Week Range:
$37.66
$61.61
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
41.37 | 2.84B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.53 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.11 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Trend Tracker for (MRUS) - Stock Traders Daily
Wells Fargo sets $91 target on Merus stock, cites mCRC potential - Investing.com
Wells Fargo Initiates Merus at Overweight With $91 Price Target -February 07, 2025 at 08:40 am EST - Marketscreener.com
Q1 Earnings Forecast for Merus Issued By Leerink Partnrs - MarketBeat
Merus Stock: Cancer Drug Study Results Spark Growth - sharewise
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewswire
Landmark Cancer Treatment: Merus's Bizengri Shows Promising Results for Untreatable Lung & Pancreatic Cancers - StockTitan
KBC Group NV Boosts Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
Analysts Set Merus (NASDAQ:MRUS) PT at $85.64 - MarketBeat
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff (NASDAQ:MRUS) - Seeking Alpha
Merus (NASDAQ:MRUS) Short Interest Down 15.5% in December - MarketBeat
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Will Merus' First Commercialized Drug, Bizengri, Drive Revenue Growth And Propel Stock Price? - RTTNews
(MRUS) Investment Analysis - Stock Traders Daily
Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth - Yahoo Finance
What's Going On With Merus Stock Monday?Biohaven (NYSE:BHVN), Merus (NASDAQ:MRUS) - Benzinga
Biohaven & Merus Team Up to Develop Novel Bispecific ADC Therapies - Contract Pharma
Merus (NASDAQ:MRUS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Merus and Biohaven to co-develop three novel bispecific ADC programs - MSN
Merus and Biohaven link up on ADC programs - The Pharma Letter
Merus and Biohaven to co-develop three novel bispecific ADC programs (NASDAQ:MRUS) - Seeking Alpha
Merus and Biohaven Partner to Develop Next-Generation Cancer-Fighting ADC Therapies - StockTitan
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - The Manila Times
Merus (NASDAQ:MRUS) Stock Price Up 5.1%Here's What Happened - MarketBeat
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday - Benzinga
Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’ - MSN
(MRUS) Long Term Investment Analysis - Stock Traders Daily
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
Analysts Set Merus (NASDAQ:MRUS) Target Price at $85.64 - MarketBeat
4,122 Shares in Merus (NASDAQ:MRUS) Bought by MML Investors Services LLC - Defense World
State Street Corp Sells 9,809 Shares of Merus (NASDAQ:MRUS) - Defense World
Swelling losses haven't held back gains for Merus (NASDAQ:MRUS) shareholders since they're up 201% over 5 years - Simply Wall St
HighTower Advisors LLC Purchases Shares of 7,231 Merus (NASDAQ:MRUS) - Defense World
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - The Manila Times
US FDA approves Merus' therapy to treat lung, pancreatic cancers - MSN
Merus Launches Phase 2 Trial for Novel Cancer Drug Petosemtamab in Advanced Colorectal Cancer - StockTitan
Merus N.V.'s SWOT analysis: antibody innovator's stock faces pivotal year - Investing.com
Franklin Resources Inc. Acquires 150,341 Shares of Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Technical Data - Stock Traders Daily
Lord Abbett & CO. LLC Purchases 328,316 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Janus Henderson Group PLC Has $944,000 Stake in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) versus Can-Fite BioPharma (NYSE:CANF) Critical Survey - Defense World
Merus (NASDAQ:MRUS) Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight - Insider Monkey
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):